5 Key Takeaways

• 1

  AAVantgarde Bio presented early data on gene therapies for Usher syndrome and Stargardt disease at the 2025 ARVO meeting.

• 2

  The phase 1/2 LUCE-1 trial of AAVB-081 showed no serious adverse events among the first 8 participants.

• 3

  One participant in the AAVB-081 trial experienced significant vision improvement after 6 months.

• 4

  Preclinical findings for AAVB-039 indicated no unexpected safety concerns, supporting a first-in-human trial.

• 5

  AAVantgarde's gene therapies utilize dual AAV vector platforms to overcome limitations of standard AAV technology.